These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 8999802)
1. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Huang X; Molema G; King S; Watkins L; Edgington TS; Thorpe PE Science; 1997 Jan; 275(5299):547-50. PubMed ID: 8999802 [TBL] [Abstract][Full Text] [Related]
2. A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors. Burrows FJ; Watanabe Y; Thorpe PE Cancer Res; 1992 Nov; 52(21):5954-62. PubMed ID: 1394221 [TBL] [Abstract][Full Text] [Related]
3. Specific tissue factor delivery using a tumor-homing peptide for inducing tumor infarction. Shi Q; Zhang Y; Liu S; Liu G; Xu J; Zhao X; Anderson GJ; Nie G; Li S Biochem Pharmacol; 2018 Oct; 156():501-510. PubMed ID: 30222966 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature. Kessler T; Bieker R; Padró T; Schwöppe C; Persigehl T; Bremer C; Kreuter M; Berdel WE; Mesters RM Clin Cancer Res; 2005 Sep; 11(17):6317-24. PubMed ID: 16144936 [TBL] [Abstract][Full Text] [Related]
5. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Bieker R; Kessler T; Schwöppe C; Padró T; Persigehl T; Bremer C; Dreischalück J; Kolkmeyer A; Heindel W; Mesters RM; Berdel WE Blood; 2009 May; 113(20):5019-27. PubMed ID: 19179306 [TBL] [Abstract][Full Text] [Related]
6. Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Ran S; Gao B; Duffy S; Watkins L; Rote N; Thorpe PE Cancer Res; 1998 Oct; 58(20):4646-53. PubMed ID: 9788617 [TBL] [Abstract][Full Text] [Related]
7. Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Hu Z; Sun Y; Garen A Proc Natl Acad Sci U S A; 1999 Jul; 96(14):8161-6. PubMed ID: 10393965 [TBL] [Abstract][Full Text] [Related]
8. pHLIP-mediated targeting of truncated tissue factor to tumor vessels causes vascular occlusion and impairs tumor growth. Li S; Tian Y; Zhao Y; Zhang Y; Su S; Wang J; Wu M; Shi Q; Anderson GJ; Thomsen J; Zhao R; Ji T; Wang J; Nie G Oncotarget; 2015 Sep; 6(27):23523-32. PubMed ID: 26143637 [TBL] [Abstract][Full Text] [Related]
9. Potent antitumor effects of an antitumor endothelial cell immunotoxin in a murine vascular targeting model. Burrows FJ; Overholser JP; Thorpe PE Cell Biophys; 1994; 24-25():15-25. PubMed ID: 7736519 [TBL] [Abstract][Full Text] [Related]
10. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Hu P; Yan J; Sharifi J; Bai T; Khawli LA; Epstein AL Cancer Res; 2003 Aug; 63(16):5046-53. PubMed ID: 12941833 [TBL] [Abstract][Full Text] [Related]
11. Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction. Stucke-Ring J; Ronnacker J; Brand C; Höltke C; Schliemann C; Kessler T; Schmidt LH; Harrach S; Mantke V; Hintelmann H; Hartmann W; Wardelmann E; Lenz G; Wünsch B; Müller-Tidow C; Mesters RM; Schwöppe C; Berdel WE Oncotarget; 2016 Dec; 7(50):82458-82472. PubMed ID: 27738341 [TBL] [Abstract][Full Text] [Related]
12. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Burrows FJ; Thorpe PE Proc Natl Acad Sci U S A; 1993 Oct; 90(19):8996-9000. PubMed ID: 7692443 [TBL] [Abstract][Full Text] [Related]
13. Preparation of truncated tissue factor antineuropilin-1 monoclonal antibody conjugate and identification of its selective thrombosis in tumor blood vessels. Xu P; Zou M; Wang S; Wang L; Wang L; Luo F; Wu T; Yan J Anticancer Drugs; 2019 Jun; 30(5):441-450. PubMed ID: 30807552 [TBL] [Abstract][Full Text] [Related]
14. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile. Dreischalück J; Schwöppe C; Spieker T; Kessler T; Tiemann K; Liersch R; Schliemann C; Kreuter M; Kolkmeyer A; Hintelmann H; Mesters RM; Berdel WE Int J Oncol; 2010 Dec; 37(6):1389-97. PubMed ID: 21042706 [TBL] [Abstract][Full Text] [Related]
15. [Humanized monoclonal antibody TNT-3-mediated truncated tissue factor for the treatment of H22 hepatoma-bearing mice]. Huang ZJ; Wang R; Liu ZZ; Wang SY; Yan JH; Luo Q Zhonghua Zhong Liu Za Zhi; 2012 Apr; 34(4):249-53. PubMed ID: 22781034 [TBL] [Abstract][Full Text] [Related]
16. Soluble tissue factor induces coagulation on tumor endothelial cells in vivo if coadministered with low-dose lipopolysaccharides. Philipp J; Dienst A; Unruh M; Wagener A; Grunow A; Engert A; Fries JW; Gottstein C Arterioscler Thromb Vasc Biol; 2003 May; 23(5):905-10. PubMed ID: 12649087 [TBL] [Abstract][Full Text] [Related]
17. Tumor Growth Inhibition via Occlusion of Tumor Vasculature Induced by N-Terminally PEGylated Retargeted Tissue Factor tTF-NGR. Brand C; Fröhlich M; Ring J; Schliemann C; Kessler T; Mantke V; König S; Lücke M; Mesters RM; Berdel WE; Schwöppe C Mol Pharm; 2015 Oct; 12(10):3749-58. PubMed ID: 26310827 [TBL] [Abstract][Full Text] [Related]
18. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Kim ES; Serur A; Huang J; Manley CA; McCrudden KW; Frischer JS; Soffer SZ; Ring L; New T; Zabski S; Rudge JS; Holash J; Yancopoulos GD; Kandel JJ; Yamashiro DJ Proc Natl Acad Sci U S A; 2002 Aug; 99(17):11399-404. PubMed ID: 12177446 [TBL] [Abstract][Full Text] [Related]
19. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Nilsson F; Kosmehl H; Zardi L; Neri D Cancer Res; 2001 Jan; 61(2):711-6. PubMed ID: 11212273 [TBL] [Abstract][Full Text] [Related]